{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Fibroblasts", "query": { "condition": "Skin Fibroblasts" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Fibroblasts&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:55:32.624Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06164951", "title": "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib 0.25 mg/kg/day", "type": "DRUG" }, { "name": "Placebo Comparator 0.25 mg/kg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 114, "start_date": "2023-11-10", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06164951" }, { "nct_id": "NCT03789175", "title": "Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Skin Fibroblasts", "Muscle Weakness" ], "interventions": [ { "name": "Nicotinamide Riboside (NR)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1, "start_date": "2019-03-25", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03789175" }, { "nct_id": "NCT02810951", "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epidermolysis Bullosa Dystrophica, Recessive" ], "interventions": [ { "name": "FCX-007", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Castle Creek Biosciences, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 6, "start_date": "2016-07-01", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 2, "location_summary": "Stanford, California • Aurora, Colorado", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02810951" }, { "nct_id": "NCT04265651", "title": "Study of Infigratinib in Children With Achondroplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib 0.016 mg/kg", "type": "DRUG" }, { "name": "Infigratinib 0.032 mg/kg", "type": "DRUG" }, { "name": "Infigratinib 0.064 mg/kg", "type": "DRUG" }, { "name": "Infigratinib 0.128 mg/kg", "type": "DRUG" }, { "name": "Infigratinib 0.25 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "3 Years to 11 Years" }, "enrollment_count": 84, "start_date": "2020-03-10", "completion_date": "2024-10-21", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 5, "location_summary": "Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04265651" }, { "nct_id": "NCT03875079", "title": "A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "RO6874281", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2019-06-24", "completion_date": "2022-07-14", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875079" }, { "nct_id": "NCT07432633", "title": "[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Epithelial Ovarian Cancer", "Gastric Cancer", "Invasive Lobular Breast Carcinoma", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "[18F]FPyQCP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blue Earth Diagnostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 71, "start_date": "2026-03-18", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07432633" }, { "nct_id": "NCT05145010", "title": "Extension Study of Infigratinib in Children With Achondroplasia (ACH)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 300, "start_date": "2021-12-06", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 8, "location_summary": "Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05145010" }, { "nct_id": "NCT05325866", "title": "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 260, "start_date": "2022-09-23", "completion_date": "2026-01-28", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 10, "location_summary": "Duarte, California • Orange, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05325866" }, { "nct_id": "NCT00895271", "title": "Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Immunodeficiency", "DOCK8", "Virus Susceptibility" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "2 Years to 85 Years" }, "enrollment_count": 200, "start_date": "2009-06-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895271" }, { "nct_id": "NCT03372746", "title": "Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "AMD" ], "interventions": [], "intervention_types": [], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 187, "start_date": "2018-05-23", "completion_date": "2019-03-21", "has_results": false, "last_update_posted_date": "2019-04-05", "last_synced_at": "2026-05-21T22:55:32.624Z", "location_count": 14, "location_summary": "Beverly Hills, California • Miami, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03372746" } ] }